Scientists dig into tissue samples to unravel lung scarring mystery

NCT ID NCT00084305

Ongoing Knowledge-focused Sponsor: National Human Genome Research Institute (NHGRI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could reveal new clues about what causes pulmonary fibrosis, potentially pointing toward future treatments.
What could go wrong: This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hermansky-Pudlak syndrome idiopathic pulmonary fibrosis post-COVID-19 disorder pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HERMANSKY-PUDLAK SYNDROME (HPS) PULMONARY FIBROSIS

Contacts and locations

Show contact details

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.